NCT05276973 - Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

January 30, 2025

Study Completion Date

February 26, 2026

Conditions

Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Unresectable Fallopian Tube Endometrioid AdenocarcinomaUnresectable Fallopian Tube High Grade Serous AdenocarcinomaUnresectable Ovarian Endometrioid AdenocarcinomaUnresectable Ovarian High Grade Serous AdenocarcinomaUnresectable Primary Peritoneal Endometrioid AdenocarcinomaUnresectable Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

PROCEDURE

Biopsy

Undergo biopsy

DRUG

Carboplatin

Given IV

DRUG

Ipatasertib

Given PO

DRUG

Paclitaxel

Given IV

Trial Locations (8)

19111

Fox Chase Cancer Center, Philadelphia

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

30912

Augusta University Medical Center, Augusta

44195

Cleveland Clinic Foundation, Cleveland

53226

Medical College of Wisconsin, Milwaukee

73104

University of Oklahoma Health Sciences Center, Oklahoma City

94158

UCSF Medical Center-Mission Bay, San Francisco

02905

Women and Infants Hospital, Providence